muscular disease: Acquired, familial, and congenital disorders of skeletal muscle and smooth muscle.
Muscle wasting and atrophy, not elsewhere classified
DOID EFO Endpoint Browser PheWeb
M13_MUSCLEATROPH
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
214 |
4. Check minimum number of eventsNone |
214 |
5. Include endpointsNone |
214 |
6. Filter based on genotype QC (FinnGen only) |
214 |
Control definitions (FinnGen only)
- Control exclude
- M13_SOFTTISSUE
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M62
- Name in latin
- Atrophia et degeneratio musculi non alibi classificatae
Similar endpoints
↥List of similar endpoints to
Muscle wasting and atrophy, not elsewhere classified
based on the number of shared cases.
Similar with more cases:
- Disorders of muscles
- Soft tissue disorders
- Diseases of the musculoskeletal system and connective tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1539 | 650 | 867 |
| Only index persons | 1277 | 562 | 715 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 58.20 | 59.33 | 57.32 |
| Only index persons | 57.86 | 58.68 | 57.22 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 214 | 97 | 117 |
| Unadjusted period prevalence (%) | 0.04 | 0.03 | 0.05 |
| Median age at first event (years) | 57.55 | 54.05 | 60.44 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 194
- Matched controls
- 1940
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M62.5
ICD-10 Finland
Muscle wasting and atrophy, not elsewhere classified
+∞
207.3
160
*
G72.9
ICD-10 Finland
Myopathy, unspecified
77.9
19.1
21
*
73310
ICD-8 Finland
Other diseases of muscle, tendon and fascia, Muscular atrophy (idiopathic)
+∞
18.0
17
*
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
18.0
15.7
24
15
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
7.9
14.2
33
49
7282A
ICD-9 Finland
Disorders of muscle, ligament and fascia, Muscular wasting and disuse atrophy, not elsewhere classified
+∞
13.7
13
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.9
12.1
42
104
M79.6
ICD-10 Finland
Pain in limb
3.2
10.8
67
271
N03AX12
ATC
gabapentin; oral
4.1
9.2
37
106
G56.2
ICD-10 Finland
Lesion of ulnar nerve
13.4
9.0
15
12
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
6.8
8.9
22
36
M54.1
ICD-10 Finland
Radiculopathy
10.1
8.5
16
17
G12.9
ICD-10 Finland
Spinal muscular atrophy, unspecified
+∞
8.4
8
*
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
15.4
8.3
13
9
N02AX02
ATC
tramadol; systemic, rectal
2.5
8.2
87
475
N03AX16
ATC
pregabalin; oral
3.1
7.9
48
188
ACC59
NOMESCO Finland
Decompression and freeing of adhesions of peripheral nerve: other or unspecified
9.5
7.7
15
17
M15.9
ICD-10 Finland
Polyarthrosis, unspecified
6.5
7.6
19
32
G56.0
ICD-10 Finland
Carpal tunnel syndrome
4.2
7.6
28
74
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.9
7.4
30
86
NXL00
NOMESCO Finland
Biopsy of muscle
+∞
7.3
7
*
M17.1
ICD-10 Finland
Other primary gonarthrosis
2.9
7.2
47
193
M17.0
ICD-10 Finland
Primary gonarthrosis, bilateral
3.7
7.1
31
95
M13.9
ICD-10 Finland
Arthritis, unspecified
4.5
7.0
24
59
TAB00
NOMESCO Finland
Lumbar puncture
6.1
7.0
18
32
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.9
6.9
45
184
M75.4
ICD-10 Finland
Impingement syndrome of shoulder
17.4
6.8
10
6
ACC53
NOMESCO Finland
Release of ulnar nerve
41.5
6.8
8
*
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
4.7
6.8
22
51
L28
ICPC
Limited function/disability (L)
2.9
6.6
42
169
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.4
6.6
64
328
M54.5
ICD-10 Finland
Low back pain
2.4
6.4
65
337
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
4.8
6.4
20
45
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
7.4
6.3
14
20
M60.8
ICD-10 Finland
Other myositis
+∞
6.3
6
*
G71.08
ICD-10 Finland
Other muscular dystrophy
+∞
6.3
6
*
SPAT1229
SPAT
Assessment of need for aid
4.1
6.2
23
61
M21.4
ICD-10 Finland
Flat foot [pes planus] (acquired)
13.1
6.1
10
8
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
120
750
2.37
8.71
6.5
6.7
1.2
1.2
mmol/l
0.05
114
680
126
812
2.34
8.42
7.3
7.6
1.2
1.2
mmol/l
0.33
113
691
16
31
5.50
8.06
1.7
1.3
—
—
—
0
0
110
731
2.04
6.12
4.8
4.6
34.4
35.2
g/l
0.77
101
684
151
1151
2.06
5.45
4.8
3.6
11.8
12.4
mm/h
0.22
142
1048
50
268
2.13
4.80
2.8
4.1
0.8
0.8
mmol/l
0.14
44
253
117
845
1.85
4.64
5.7
6.6
11.4
11.6
umol/l
0.07
111
802
8
8
10.33
4.56
1.0
1.0
—
—
—
0
0
9
12
7.77
4.40
1.0
1.1
—
—
—
0
0
55
317
1.99
4.32
1.9
1.7
926.8
1125.6
nmol/l
1.13
44
235
9
13
7.17
4.20
1.0
1.1
—
—
—
0
0
6
5
12.29
3.78
1.2
1.0
—
—
—
0
0
120
910
1.73
3.73
7.8
9.1
4.5
4.1
e9/l
0.73
112
801
93
660
1.72
3.66
2.2
1.9
104.4
90.4
pmol/l
1.29
57
338
10
30
3.45
2.94
1.2
1.3
—
—
—
0
0
6
9
6.82
2.88
1.0
1.0
—
—
—
0
0
72
504
1.65
2.85
3.9
3.3
1835.0
1464.1
ng/l
0.40
66
436
86
631
1.61
2.81
2.2
2.1
81.3
75.3
nmol/l
1.02
80
561
36
207
1.89
2.80
1.3
1.2
14.4
39.0
iu/ml
1.65
13
64
85
624
1.60
2.76
5.3
3.8
78.2
39.7
ng/l
0.91
63
467
21
99
2.24
2.75
1.4
1.3
—
—
—
0
0
97
737
1.58
2.71
3.5
4.2
—
—
—
0
0
36
210
1.86
2.68
8.6
9.5
1.4
1.2
mmol/l
0.11
26
167
46
296
1.71
2.47
1.4
1.2
0.5
1.1
u/ml
1.53
13
82
24
125
2.04
2.47
1.7
1.6
—
—
—
0
0
34
200
1.83
2.47
1.3
1.2
2.8
13.3
u/ml
—
7
77
55
379
1.61
2.27
2.7
2.8
335.8
10298.2
umol/l
2.40
48
317
68
498
1.54
2.15
3.1
2.3
54.2
55.8
u/l
0.19
63
456
74
553
1.52
2.13
3.1
3.7
2.3
2.4
mmol/l
0.06
64
492
56
394
1.57
2.11
3.0
2.0
3.1
3.2
mg/l
0.05
50
335
5
10
5.09
2.08
2.6
1.9
—
—
—
0
0
14
64
2.27
1.99
1.5
1.2
—
—
—
0
0
5
11
4.63
1.95
5.8
2.3
13.9
13.2
%
—
5
11
10
40
2.57
1.86
1.1
1.3
—
—
—
0
0
47
327
1.56
1.85
4.1
3.5
4502.8
300.7
ng/l
0.60
39
274
35
229
1.63
1.77
2.5
2.4
22.2
22.6
%
0.06
27
199
49
348
1.53
1.76
1.6
1.8
100000407.1
13468439.2
pmol/l
0.40
38
297
95
778
1.40
1.61
4.7
3.5
0.0
0.0
estimate
0.00
13
143
118
1007
1.38
1.54
6.0
5.2
7.0
6.8
mmol/l
0.39
113
940
7
27
2.64
1.53
1.0
1.3
—
—
—
0
0
53
394
1.46
1.52
1.5
1.5
23.9
20.3
nmol/l
0.77
47
333
46
334
1.48
1.48
1.9
1.6
1.3
1.5
mg/l
0.22
39
265
176
1625
1.47
1.33
20.9
14.3
23.7
26.7
mg/l
0.69
155
1285
9
45
2.04
1.25
1.6
1.4
—
—
—
0
0
93
788
1.32
1.18
4.8
3.5
0.0
0.0
estimate
0.00
13
140
30
212
1.48
1.12
5.3
4.3
31.0
30.6
%
0.06
24
131
43
326
1.40
1.11
2.7
2.9
2.5
2.5
mmol/l
0.14
37
290
18
113
1.65
1.09
4.6
3.8
5.2
5.2
kpa
0.03
18
105
38
284
1.41
1.07
2.0
1.8
—
—
—
0
0
79
664
1.30
1.04
3.3
2.4
176.1
148.5
ug/l
0.45
74
608
91
780
1.29
1.03
6.4
4.7
0.0
0.0
estimate
0.00
14
143
16
100
1.65
1.00
1.5
1.8
—
—
—
0
0
0
29
0.00
0.98
0.0
1.8
—
—
—
0
0
10
54
1.89
0.98
2.6
2.5
—
—
—
0
0
7
36
1.98
0.98
2.9
1.5
—
—
—
0
0
28
201
1.45
0.97
10.0
7.4
—
—
—
0
0
58
471
1.32
0.97
2.8
3.1
0.1
0.6
e6/l
3.77
48
357
6
29
2.10
0.90
1.2
1.6
—
—
—
0
0
129
1168
1.26
0.90
3.7
3.6
15.3
14.9
pmol/l
0.81
119
1032
8
42
1.94
0.89
1.6
1.4
—
—
—
0
0
6
31
1.96
0.85
4.7
4.5
386.7
362.8
umol/l
—
6
24
6
33
1.84
0.79
1.2
1.6
—
—
—
0
0
5
24
2.11
0.75
1.0
1.6
—
—
—
0
0
9
57
1.60
0.72
1.8
1.6
—
—
—
0
0
21
154
1.40
0.68
3.2
3.9
3.2
1.8
mmol/l
1.06
15
123
12
78
1.57
0.67
2.8
4.4
25.2
24.0
mmol/l
0.68
12
72
36
289
1.30
0.67
2.3
2.7
0.8
1.0
e6/l
0.43
26
169
5
28
1.80
0.66
1.0
1.5
—
—
—
0
0
27
208
1.34
0.66
1.9
1.8
—
—
—
0
0
14
96
1.49
0.63
10.9
10.2
24.1
24.8
mmol/l
0.39
14
91
5
30
1.68
0.62
1.4
1.7
—
—
—
0
0
26
202
1.33
0.61
1.6
1.4
—
—
—
0
0
163
1549
1.22
0.57
5.9
5.8
39.6
40.4
mmol/mol
0.49
152
1430
70
618
1.20
0.56
5.6
3.6
—
—
—
0
0
47
547
0.82
0.55
3.4
4.5
21.5
21.1
%
0.07
22
257
69
611
1.19
0.54
3.7
3.2
—
—
—
0
0
9
62
1.47
0.54
2.3
1.8
—
—
—
0
0
9
134
0.66
0.53
1.6
1.7
—
—
—
0
0
18
135
1.36
0.53
2.7
2.8
51.8
62.5
ml/min/173m2
—
6
57
156
1481
1.20
0.53
4.7
4.2
2.0
2.0
mu/l
0.15
144
1318
26
207
1.29
0.52
1.9
1.8
—
—
—
0
0
49
423
1.21
0.50
5.6
3.8
0.0
0.0
estimate
0.00
13
134
7
46
1.54
0.49
1.3
1.2
—
—
—
0
0
7
46
1.54
0.49
1.3
1.2
—
—
—
0
0
33
391
0.82
0.46
2.3
2.9
0.8
0.8
ug/l
0.09
21
256
97
894
1.16
0.45
2.5
2.8
—
—
—
0
0
16
122
1.34
0.44
1.5
1.8
374.8
409.0
nmol/l
0.41
16
113
0
15
0.00
0.41
0.0
1.6
—
14.1
—
0
9
0
15
0.00
0.41
0.0
1.0
—
1.5
—
0
15
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
44.6
—
0
13
5
35
1.44
0.39
1.0
1.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.7
—
—
—
0
0
45
397
1.17
0.37
2.2
2.4
—
—
—
0
0
6
41
1.48
0.36
1.3
1.7
—
—
—
0
0
163
1683
0.87
0.35
5.1
4.9
2.8
2.7
mmol/l
1.15
149
1533
6
44
1.37
0.34
1.3
1.6
—
—
—
0
0
6
44
1.37
0.34
1.3
1.4
—
—
—
0
0
160
1653
0.87
0.34
4.9
4.4
4.7
4.5
mmol/l
1.35
146
1523
159
1641
0.88
0.31
4.7
4.3
1.5
1.4
mmol/l
0.21
145
1493
8
64
1.26
0.28
1.0
1.1
—
—
—
0
0
8
64
1.26
0.28
1.3
1.4
—
—
—
0
0
11
87
1.28
0.25
3.2
2.6
1.3
1.2
%
0.33
11
87
154
1582
0.91
0.23
4.5
4.0
1.3
1.3
mmol/l
0.25
138
1437
5
40
1.26
0.22
1.2
1.3
—
—
—
0
0
13
107
1.23
0.22
13.4
9.4
94.5
93.8
%
0.32
13
107
0
10
0.00
0.21
0.0
2.9
—
211.8
—
0
10
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.1
—
2.8
—
0
13
180
1770
1.11
0.17
12.6
9.9
27.5
26.3
u/l
0.27
175
1696
166
1628
1.09
0.16
4.8
4.5
5.9
6.0
mmol/l
0.57
155
1475
109
1054
1.07
0.16
4.2
3.0
74.0
52.1
u/l
0.50
102
984
57
538
1.08
0.16
3.4
3.9
11.9
11.4
mg/mmol
0.03
38
354
11
93
1.19
0.15
11.9
6.6
25.2
25.3
mmol/l
0.07
11
93
66
690
0.94
0.14
4.0
4.9
2.2
2.4
ug/l
0.25
52
612
22
200
1.11
0.13
1.8
1.4
—
—
—
0
0
16
175
0.91
0.09
3.9
3.4
—
—
—
0
0
7
64
1.10
0.08
1.3
1.7
—
—
—
0
0
151
1491
1.04
0.07
20.4
15.6
39.0
39.6
%
0.28
92
1029
158
1567
1.03
0.04
15.7
13.6
81.6
78.3
ml/min/173m2
1.10
145
1297
10
107
0.93
0.02
2.1
1.6
—
—
—
0
0
11
116
0.95
0.01
2.2
1.8
—
—
—
0
0
28
274
1.03
0.00
2.3
2.9
2.0
2.4
e6/l
0.14
18
155
0
5
0.00
0.00
0.0
1.0
—
1062.4
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.6
—
36.6
—
0
8
5
49
1.02
0.00
1.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
3.8
—
—
—
0
0
5
51
0.98
0.00
1.2
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
4.0
—
64.7
—
0
7
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
0.00
0.0
5.5
—
101.0
—
0
6
0
6
0.00
0.00
0.0
3.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
5
52
0.96
0.00
2.4
2.2
21.5
25.0
mmol/l
—
5
42
Mortality – FinRegistry
↥Association
Association between endpoint M13_MUSCLEATROPH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MUSCLEATROPH | 2.0 [1.43, 2.8] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.168 |
During the follow-up period (1.1.1998 — 31.12.2019), 100 out of 431 females with M13_MUSCLEATROPH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_MUSCLEATROPH | 2.175 [1.62, 2.92] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.012 |
During the follow-up period (1.1.1998 — 31.12.2019), 165 out of 582 males with M13_MUSCLEATROPH died.
Mortality risk
Mortality risk for people of age
years, who have M13_MUSCLEATROPH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.222% | 0.409% |
| 5 | 1.237% | 2.655% |
| 10 | 3.025% | 6.217% |
| 15 | 5.429% | 11.554% |
| 20 | 9.286% | 19.826% |
Relationships between endpoints
↥Index endpoint: M13_MUSCLEATROPH – Muscle wasting and atrophy, not elsewhere classified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data